Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASIS KIDS marstacimab prophylaxis study in pediatric hemophilia A or B
jRCT2071220116Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoints: Annualized bleeding rate of treated bleeding events, Incidence of adverse events and serious adverse events and 6 more. Started Jul 2023; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2071220116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220116.